Negative / Null Result ReportOpen accessMedicine· cited by 19

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study

Dipender Gill; Marios Arvanitis; Paul Carter; Ana I. Hernández Cordero; Brian Jo; Ville Karhunen; Susanna C. Larsson; Xuan Li · 2020 · Royal Society Open Science

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 have been implicated in cell entry for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). The expression of ACE2 and TMPRSS2 in the lung epithelium might have implications for the risk of SARS-CoV-2 infection and severity of COVID-19. We use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to investigate whether these exposures affect lung ACE2 and TMPRSS2 gene expression and circ

Abstract by Dipender Gill; Marios Arvanitis; Paul Carter; Ana I. Hernández Cordero; Brian Jo; Ville Karhunen; Susanna C. Larsson; Xuan Li, Royal Society Open Science (2020) — licensed CC BY 4.0.

Read the full paper (open access)